Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn’s disease
- Resource Type
- Authors
- A. Orlando; F. Mocciaro; A. Sferrazza; Mario Cottone; M. Olivo; Francesca Rossi; Fabio Tinè; Daniela Scimeca
- Source
- Alimentary Pharmacology & Therapeutics. 27:1210-1223
- Subject
- medicine.medical_specialty
Crohn's disease
Blinding
Randomization
Hepatology
business.industry
Gastroenterology
Disease
medicine.disease
Surgery
law.invention
Clinical trial
Randomized controlled trial
law
Internal medicine
Meta-analysis
Concomitant
medicine
Pharmacology (medical)
business
- Language
- ISSN
- 1365-2036
0269-2813
Summary Background Remission and response are the main outcomes to evaluate the efficacy of new treatments for Crohn’s disease (CD). Aim To explain variation of remission and response rates in active luminal CD. Methods We studied control patients from trials of biological therapies through articles retrieved by MEDLINE search (from 1997 to 2007) and by bibliography review. Thousand nine hundred and thirteen control patients from 28 trials were identified; data were extracted by three independent observers and pooled by DerSimonian and Laird random effect model; factors influencing remission and clinical response were explored by metaregression for aggregated data. Results The pooled control rates of remission and response were 17% and 33%, respectively, both with significant heterogeneity among studies (P